<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706132</url>
  </required_header>
  <id_info>
    <org_study_id>2015-08</org_study_id>
    <nct_id>NCT02706132</nct_id>
  </id_info>
  <brief_title>Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation</brief_title>
  <official_title>MSC for ABO Incompatible Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MSCs are safe and effective in reducing the
      primary nonfunction (PNF), acute rejection and Ischemic-type Biliary Lesions (ITBLs)
      morbidity in ABO-incompatible Liver Transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABO incompatible liver transplantations is considered to be a rescue option in emergency
      transplantation.The A、B antibodies to grafts bind to the graft endothelium and activate
      complement, which attracts and activates neutrophils and platelets and increases the
      permeability of the endothelium. The neutrophils exude, the platelets aggregate, and the
      small vessels of the graft get thrombosed, resulting in ischemic damage,leading nonfunction
      grafts.In addition, if the A、 B antibodies remain high level, it can lead to acute humoral
      immune rejection. A lot of research confirmed that the ABO incompatible is a risk factor of
      postoperative short- and long-term survival. And mesenchymal stromal cells (MSCs) are
      characterized by the properties of immunosuppressive and regenerative properties, which make
      MSCs great attractive in treating immunological diseases (including transplant rejection) and
      organ/tissue ischemic injury. So we conduct this clinical study,to confirm the effect of MSCs
      in ABO incompatible liver transplantation by comparing the incidence of primary nonfunction,
      acute rejection, biliary complications and survival rates.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: one year graft survival rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of acute rejection</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of ischemic-type biliary lesions</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety: rate of (serious) adverse events in the study population</measure>
    <time_frame>one year</time_frame>
    <description>adverse events include: allergic reaction, prothrombotic effects, opportunistic infections and malignancy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>The MSCs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group of patients receive allogeneic MSCs therapies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cells(MSCs)</intervention_name>
    <description>Six doses of 1*10^6/kg body weight MSCs are given, intravenously.</description>
    <arm_group_label>The MSCs group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First liver transplantation with a ABO-incompatible
             graft(B→A，AB→A，A→B，AB→B，A→O，B→O，AB→O).

          -  Ages of 18 or older.

          -  Patients receive liver transplantation due to benign end stage liver disease.

          -  Patients or legal agent must be able to give informed consent.

        Exclusion Criteria:

          -  Second or combined organ transplant recipient.

          -  Combined transplantations such as simultaneous liver/kidney transplants

          -  Malignant disease.

          -  Uncontrol bacterial, fungal, viral or parasitic infection.

          -  Withdraw or unable to finish the follow-up.

          -  Unwilling to sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Yang</last_name>
    <role>Study Chair</role>
    <affiliation>The Third Affiliated Hospital, SUN YAT-SEN University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Yang</last_name>
    <phone>862085252276</phone>
    <email>yysysu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Yingcai</last_name>
    <phone>862085252177</phone>
    <email>76207884@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Yingcai</last_name>
      <phone>862085252177</phone>
      <email>76207884@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Yang Yang</investigator_full_name>
    <investigator_title>Department of Liver Transplantation</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>ABO blood group</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

